Fate Therapeutics Announces FDA Clearance for FT536, a First-in-Class MICA/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors

Fate Therapeutics, Inc. announced that the US FDA has cleared the company’s Investigational New Drug application for FT536, an off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor NK cell product candidate.